AbbVie News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

26.07.22	European Commission Approves AbbVie's Rinvoq To Treat Moderate To Severe Ulcerative Colitis (RTTNews)
26.07.22	European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis (PR Newswire)
25.07.22	AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference (PR Newswire)
20.07.22	AbbVie To Collaborate With ISTAR Medical; To Pay $60 Mln To Further Develop MINIject (RTTNews)
20.07.22	AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma (PR Newswire)
18.07.22	AbbVie: EMA's CHMP To Review Marketing Authorization Application For Migraine Drug Atogepant (RTTNews)
18.07.22	AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine (PR Newswire)
08.07.22	AbbVie to Host Second-Quarter 2022 Earnings Conference Call (PR Newswire)
27.06.22	Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities (PR Newswire)
27.06.22	AbbVie: Europe's CHMP Recommends To Approve Upadacitinib To Treat Active Nr-axSpA Patients (RTTNews)
27.06.22	CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (PR Newswire)
24.06.22	New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer (PR Newswire)
23.06.22	AbbVie Declares Quarterly Dividend (PR Newswire)
22.06.22	AbbVie: Health Canada Approves Label Extension For MAVIRET To Include Use In Paediatric Patients (RTTNews)
21.06.22	AbbVie Files SNDA For Atogepant For Label Expansion (RTTNews)
21.06.22	AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine (PR Newswire)
17.06.22	Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry (PR Newswire)
17.06.22	AbbVie: FDA Approves SKYRIZI In Treatment Of Crohn's Disease (RTTNews)
17.06.22	SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults (PR Newswire)
11.06.22	AbbVie : Phase 2 Trial Of Epcoritamab Shows Clinically Meaningful Efficacy In Large B-cell Lymphoma (RTTNews)
11.06.22	AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hemat... (PR Newswire)
10.06.22	AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients (PR Newswire)
10.06.22	AbbVie : Data Shows Venclyxto/Venclexta Combination Sustained PFS In Chronic Lymphocytic Leukemia (RTTNews)
10.06.22	New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment (PR Newswire)
07.06.22	AbbVie to Present Extensive Data from its Migraine Portfolio at the 2022 American Headache Society® (AHS) Annual Scientific Meeting (PR Newswire)
02.06.22	ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV (PR Newswire)
02.06.22	AbbVie Presents Positive Results From Phase 3 Trials Of Upadacitinib In Axial Spondyloarthritis (RTTNews)
01.06.22	AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022 (PR Newswire)
27.05.22	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis (PR Newswire)
27.05.22	The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease (PR Newswire)
24.05.22	ABBV LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important June 6 Deadline in Securities Class Action - ABBV (PR Newswire)
24.05.22	AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress (PR Newswire)
23.05.22	AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting (PR Newswire)
23.05.22	AbbVie:CHMP Recommends European Commission Approval Of Upadacitinib For Ulcerative Colitis Treatment (RTTNews)
23.05.22	CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis (PR Newswire)
20.05.22	AbbVie Submits NDA For ABBV-951 To FDA For Treatment Of Advanced Parkinson's Disease (RTTNews)
20.05.22	AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease (PR Newswire)
16.05.22	AbbVie to Showcase Depth of Gastroenterology Portfolio and Pipeline at Digestive Disease Week® (PR Newswire)
16.05.22	AbbVie Receives Option To License Certain IL-2 Muteins, Including CUG252, From Cugene (RTTNews)
16.05.22	AbbVie and Cugene Announce Collaboration in Autoimmune Diseases (PR Newswire)
14.05.22	ROSEN, A TOP RANKED FIRM, Encourages AbbVie Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
12.05.22	AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses (PR Newswire)
12.05.22	AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education (PR Newswire)
11.05.22	AbbVie Announces Positive Topline Results From U-ENDURE Phase 3 Study Evaluating Upadacitinib (RTTNews)
11.05.22	Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease (PR Newswire)
02.05.22	Rosen, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV (PR Newswire)
30.04.22	FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitis (RTTNews)
29.04.22	RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis (PR Newswire)
29.04.22	AbbVie Shares Hurt On Reduced Earnings Outlook (RTTNews)
29.04.22	AbbVie Q1 Income Rises (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester